Literature DB >> 20163988

New aspects in vascular gene therapy.

Henna Karvinen1, Seppo Ylä-Herttuala.   

Abstract

Advances in clinical gene therapy have been modest although significant progress has been made during the past few years. New viruses have been introduced and new results have been collected from preclinical and clinical studies. This review will focus on cardiovascular and especially proangiogenic gene therapy. Recent results from preclinical developments and clinical trials will be discussed. Copyright 2010 Elsevier Ltd. All rights reserved.

Mesh：

Year:  2010        PMID： 20163988     DOI： 10.1016/j.coph.2010.01.004

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  14 in total

1.  Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk.

Authors:  Helen E Chick; Ali Nowrouzi; Raffaele Fronza; Robert A McDonald; Nicole M Kane; Raul Alba; Christian Delles; William C Sessa; Manfred Schmidt; Adrian J Thrasher; Andrew H Baker
Journal:  Hum Gene Ther       Date:  2012-10-26       Impact factor: 5.695

2.  Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB.

Authors:  Andrea Banfi; Georges von Degenfeld; Roberto Gianni-Barrera; Silvia Reginato; Milton J Merchant; Donald M McDonald; Helen M Blau
Journal:  FASEB J       Date:  2012-03-05       Impact factor: 5.191

Review 3.  Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery.

Authors:  Joel C Sunshine; Corey J Bishop; Jordan J Green
Journal:  Ther Deliv       Date:  2011-04

Review 4.  Gene therapy from the perspective of systems biology.

Authors:  Feilim Mac Gabhann; Brian H Annex; Aleksander S Popel
Journal:  Curr Opin Mol Ther       Date:  2010-10

Review 5.  Gene delivery technologies for cardiac applications.

Authors:  M G Katz; A S Fargnoli; L A Pritchette; C R Bridges
Journal:  Gene Ther       Date:  2012-03-15       Impact factor: 5.250

6.  Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164.

Authors:  Veronica Sacchi; Rainer Mittermayr; Joachim Hartinger; Mikaël M Martino; Kristen M Lorentz; Susanne Wolbank; Anna Hofmann; Remo A Largo; Jeffrey S Marschall; Elena Groppa; Roberto Gianni-Barrera; Martin Ehrbar; Jeffrey A Hubbell; Heinz Redl; Andrea Banfi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

7.  Controlled angiogenesis in the heart by cell-based expression of specific vascular endothelial growth factor levels.

Authors:  Ludovic F Melly; Anna Marsano; Aurelien Frobert; Stefano Boccardo; Uta Helmrich; Michael Heberer; Friedrich S Eckstein; Thierry P Carrel; Marie-Noëlle Giraud; Hendrik T Tevaearai; Andrea Banfi
Journal:  Hum Gene Ther Methods       Date:  2012-10       Impact factor: 2.396

8.  Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent.

Authors:  Edin Mujagic; Roberto Gianni-Barrera; Marianna Trani; Abdulsamie Patel; Lorenz Gürke; Michael Heberer; Thomas Wolff; Andrea Banfi
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

9.  Synthetic poly(ester amine) and poly(amido amine) nanoparticles for efficient DNA and siRNA delivery to human endothelial cells.

Authors:  Stephany Y Tzeng; Peter H Yang; Warren L Grayson; Jordan J Green
Journal:  Int J Nanomedicine       Date:  2011-12-13

10.  Early vessel destabilization mediated by Angiopoietin-2 and subsequent vessel maturation via Angiopoietin-1 induce functional neovasculature after ischemia.

Authors:  Di Qin; Teresa Trenkwalder; Seungmin Lee; Omary Chillo; Elisabeth Deindl; Christian Kupatt; Rabea Hinkel
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.